Core Viewpoint - Fangsheng Pharmaceutical (603998) announced that its wholly-owned subsidiary, Guangdong Fangsheng Jianmeng Pharmaceutical Co., Ltd., has received the Clinical Trial Approval Notice from the National Medical Products Administration for the development of the generic drug RuLuGoli Tablets, which is a GnRH receptor antagonist for the treatment of advanced prostate cancer in adults [1] Company Summary - The RuLuGoli Tablets have not yet been launched in China, and there are currently no original or generic products approved for sale in the country [1] - Other companies, such as Haibu Pharmaceutical and Lianhuan Pharmaceutical (600513), have also received clinical trial approvals and plan to conduct related clinical trials [1]

方盛制药10月15日公告，全资子公司方盛健盟化药仿制药研发项目瑞卢戈利片收到国家药品监督管理局 核准签发的《药物临床试验批准通知书》。瑞卢戈利片为一种促性腺激素释放激素(GnRH)受体拮抗 剂，用于治疗成人晚期前列腺癌。 ...